Not yet in the clinic, Pardes Bio’s Covid-19 pill still fills in Foresite’s blank check

Pardes Biosciences advanced from concept to drug candidate in less than nine months. The preclinical biotech is developing an oral antiviral for Covid-19 and other coronavirus infections and it is going public in a SPAC merger that will infuse it with $276 million.